da Silva Cendon Duran, Camila and Barreto Santiago, Mittermayer (2020) Cutaneous Vasculitis During Secukinumab Treatment. European Journal of Case Reports in Internal Medicine, 7 (10). pp. 1-4. ISSN ISSN: 2284-2594
|
Text
1815-Article Text-15452-1-10-20200727.pdf - Published Version Download (281kB) | Preview |
Abstract
Secukinumab is an inhibitor of interleukin IL-17A, and is mainly used in the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis. Although rarely, this drug may induce paradoxical reactions, such as cutaneous vasculitis. Worldwide, only four previous cases of vasculitis induced by secukinumab have been reported. We herein report the first case described in Brazil of cutaneous vasculitis due to secukinumab in a patient with peripheral spondyloarthritis who demonstrated good resolution after withdrawal of the drug and initiation of etanercept. Clinicians should be aware of this rare but potentially serious adverse effect of secukinumab.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Vasculitis, secukinumab, biological therapy |
| Subjects: | 600 Tecnologia - Scienze applicate 600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) 600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) > 616 Malattie (classificare qui la Clinica medica, la medicina basata sull'evidenza, la Medicina interna, la Medicina sperimentale) |
| Depositing User: | Marina Spanti |
| Date Deposited: | 15 Dec 2021 13:37 |
| Last Modified: | 15 Dec 2021 13:37 |
| URI: | http://eprints.bice.rm.cnr.it/id/eprint/21016 |
Actions (login required)
 |
View Item |
